{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:25:12Z","timestamp":1790846712926,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.encep.2021.09.004","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T07:33:38Z","timestamp":1638603218000},"page":"313-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Les \u00e9chelles anticholinergiques\u00a0: usage en psychiatrie et mise \u00e0 jour de l\u2019\u00e9chelle d\u2019impr\u00e9gnation anticholinergique"],"prefix":"10.1016","volume":"48","author":[{"given":"H.","family":"Javelot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Runge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pospieszynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schneiderlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Armand-Branger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.G.F.","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Drapier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Haffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yrondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hingray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2021.09.004_bib0405","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2019.0676","article-title":"Preventing Alzheimer disease by deprescribing anticholinergic medications","author":"Campbell","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.encep.2021.09.004_bib0410","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000010643","article-title":"Association of anticholinergic medication and AD biomarkers with incidence of MCI among cognitively normal older adults","author":"Weigand","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.encep.2021.09.004_bib0415","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00228-013-1499-3","article-title":"Systematic review of anticholinergic risk scales in older adults","volume":"69","author":"Dur\u00e1n","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.encep.2021.09.004_bib0420","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12877-015-0029-9","article-title":"Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review","volume":"15","author":"Salahudeen","year":"2015","journal-title":"BMC Geriatr"},{"issue":"4","key":"10.1016\/j.encep.2021.09.004_bib0425","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.therap.2016.12.010","article-title":"The anticholinergic impregnation scale: towards the elaboration of a scale adapted to prescriptions in French psychiatric settings","volume":"72","author":"Briet","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.encep.2021.09.004_bib0430","first-page":"232","article-title":"Patients schizophr\u00e8nes \u00e2g\u00e9s et psychotropes","author":"Javelot","year":"2018","journal-title":"Rev Sante Ment"},{"issue":"69","key":"10.1016\/j.encep.2021.09.004_bib0435","first-page":"131","article-title":"\u00c9chelles d\u2019\u00e9valuation de l\u2019effet anticholinergique des m\u00e9dicaments","volume":"12","author":"Mebarki","year":"2012","journal-title":"NPG Neurol Psychiatr Geriatr"},{"issue":"6","key":"10.1016\/j.encep.2021.09.004_bib0440","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.encep.2021.09.004_bib0445","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/pcn.12088","article-title":"Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function","volume":"68","author":"Ogino","year":"2014","journal-title":"Psychiatry Clin Neurosci"},{"issue":"28","key":"10.1016\/j.encep.2021.09.004_bib0450","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.2174\/138161206778522056","article-title":"Muscarinic acetylcholine receptors","volume":"12","author":"Ishii","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.encep.2021.09.004_bib0455","series-title":"StatPearls","article-title":"Physiology, anticholinergic reaction [Updated 2019\u00a0Sep 8]","author":"Migirov","year":"2020"},{"issue":"Suppl 2","key":"10.1016\/j.encep.2021.09.004_bib0460","first-page":"20","article-title":"Managing anticholinergic side effects","volume":"6","author":"Lieberman","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.encep.2021.09.004_bib0465","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/bs.apha.2020.03.003","article-title":"Involvement of muscarinic receptor mechanisms in antidepressant drug action","volume":"89","author":"Witkin","year":"2020","journal-title":"Adv Pharmacol"},{"issue":"9896","key":"10.1016\/j.encep.2021.09.004_bib0470","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15\u00a0antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"10202","key":"10.1016\/j.encep.2021.09.004_bib0475","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32\u00a0oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"1\u20133","key":"10.1016\/j.encep.2021.09.004_bib0480","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2006.07.011","article-title":"A model of anticholinergic activity of atypical antipsychotic medications","volume":"88","author":"Chew","year":"2006","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.encep.2021.09.004_bib0485","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2021.09.004_bib0490","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4088\/JCP.v59n0407","article-title":"Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone","volume":"59","author":"Tracy","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"3\u20134","key":"10.1016\/j.encep.2021.09.004_bib0495","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/10401230309085687","article-title":"Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia","volume":"15","author":"Kelly","year":"2003","journal-title":"Ann Clin Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.encep.2021.09.004_bib0500","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0920-9964(03)00123-3","article-title":"Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia","volume":"68","author":"McGurk","year":"2004","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1016\/j.encep.2021.09.004_bib0505","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1176\/appi.ajp.162.5.1013","article-title":"The effects of clozapine and risperidone on spatial working memory in schizophrenia","volume":"162","author":"McGurk","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2021.09.004_bib0510","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-0179-3-14","article-title":"Antipsychotics dosage and antiparkinsonian prescriptions","volume":"3","author":"Acquaviva","year":"2007","journal-title":"Clin Pract Epidemiol Ment Health"},{"issue":"4","key":"10.1016\/j.encep.2021.09.004_bib0515","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0031-1297934","article-title":"How psychotropic polypharmacy in schizophrenia begins: a longitudinal perspective","volume":"45","author":"Shinfuku","year":"2012","journal-title":"Pharmacopsychiatry"},{"issue":"9","key":"10.1016\/j.encep.2021.09.004_bib0520","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/0269881112447988","article-title":"Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?","volume":"26","author":"Desmarais","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.encep.2021.09.004_bib0525","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/pb.23.1.22","article-title":"Audit of anticholinergic treatment in a psychiatric patient population","volume":"23","author":"Williams","year":"1999","journal-title":"Psychiatr Bull"},{"key":"10.1016\/j.encep.2021.09.004_bib0530","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ajp.2018.01.009","article-title":"Anticholinergics to treat antipsychotic-induced extrapyramidal symptoms: time to avoid this practice","volume":"31","author":"Koola","year":"2018","journal-title":"Asian J Psychiatr"},{"issue":"3","key":"10.1016\/j.encep.2021.09.004_bib0535","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-199609000-00009","article-title":"Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents","volume":"11","author":"Spivak","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.encep.2021.09.004_bib0540","first-page":"CD000204","article-title":"Anticholinergic medication for antipsychotic-induced tardive dyskinesia","volume":"1","author":"Bergman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.encep.2021.09.004_bib0545","first-page":"580","article-title":"Abuse and misuse of anticholinergic medications","volume":"42","author":"Land","year":"1991","journal-title":"Hosp Community Psychiatry"},{"issue":"2","key":"10.1016\/j.encep.2021.09.004_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2329-6488.1000263","article-title":"Anticholinergic use and misuse in psychiatry: a comprehensive and critical review","volume":"5","author":"Naja","year":"2017","journal-title":"J Alcohol Drug Depend"},{"issue":"4","key":"10.1016\/j.encep.2021.09.004_bib0555","first-page":"570","article-title":"Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders","volume":"21","author":"Mihanovi\u0107","year":"2009","journal-title":"Psychiatr Danub"},{"issue":"2\u20133","key":"10.1016\/j.encep.2021.09.004_bib0560","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0920-9964(01)00312-7","article-title":"Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder","volume":"57","author":"Robinson","year":"2002","journal-title":"Schizophr Res"},{"key":"10.1016\/j.encep.2021.09.004_bib0565","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/15622975.2019.1648871","article-title":"Extrapyramidal reactions following treatment with antidepressants: results of the AMSP multinational drug surveillance programme","volume":"21","author":"M\u00f6rkl","year":"2020","journal-title":"World J Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.encep.2021.09.004_bib0570","first-page":"115","article-title":"Do SSRI antidepressants increase the risk of extrapyramidal side effects in patients taking antipsychotics?","volume":"41","author":"Allsbrook","year":"2016","journal-title":"P T"},{"issue":"3","key":"10.1016\/j.encep.2021.09.004_bib0575","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejphar.2004.11.006","article-title":"Comparative anticholinergic activities of 10\u00a0histamine H1\u00a0receptor antagonists in two functional models","volume":"506","author":"Orzechowski","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.encep.2021.09.004_bib0580","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.psychres.2009.03.034","article-title":"Effects of benzodiazepine treatment on cortical GABA(A) and muscarinic receptors: studies in schizophrenia and rats","volume":"179","author":"McLeod","year":"2010","journal-title":"Psychiatry Res"},{"issue":"3\u20134","key":"10.1016\/j.encep.2021.09.004_bib0585","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF02245202","article-title":"An acute effect of triazolam on muscarinic cholinergic receptor binding in the human brain measured by positron emission tomography","volume":"113","author":"Suhara","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"10.1016\/j.encep.2021.09.004_bib0590","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bjp.0704968","article-title":"Inhibitory effect of diazepam on muscarinic receptor-stimulated inositol 1,4,5-trisphosphate production in rat parotid acinar cells","volume":"137","author":"Kujirai","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.encep.2021.09.004_bib0595","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1292\/jvms.11-0538","article-title":"Benzodiazepines inhibit the acetylcholine receptor-operated potassium current (IK.ACh) by different mechanisms in guinea-pig atrial myocytes","volume":"74","author":"Okada","year":"2012","journal-title":"J Vet Med Sci"},{"issue":"5","key":"10.1016\/j.encep.2021.09.004_bib0600","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1528-1157.1983.tb03429.x","article-title":"Interactions of the anticonvulsant carbamazepine with adenosine receptors. 1. Neurochemical studies","volume":"24","author":"Skerritt","year":"1983","journal-title":"Epilepsia"},{"key":"10.1016\/j.encep.2021.09.004_bib0605","doi-asserted-by":"crossref","first-page":"112989","DOI":"10.1016\/j.psychres.2020.112989","article-title":"Muscarinic M1\u00a0and M4\u00a0receptors: hypothesis driven drug development for schizophrenia","volume":"288","author":"Dean","year":"2020","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.encep.2021.09.004_bib0610","article-title":"Poids atropinique et m\u00e9dicaments anticholinergiques: int\u00e9r\u00eat et application en pratique clinique chez la personne \u00e2g\u00e9e [Atropinic burden and anticholinergic drugs: interest and application in clinical practice in the elderly]","author":"de Germay","year":"2018","journal-title":"Therapie"},{"issue":"12","key":"10.1016\/j.encep.2021.09.004_bib0615","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/0091270006292126","article-title":"The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity","volume":"46","author":"Carnahan","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"7539","key":"10.1016\/j.encep.2021.09.004_bib0620","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Nondegenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.encep.2021.09.004_bib0625","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/j.1532-5415.2008.02009.x","article-title":"Cumulative anticholinergic exposure is associated with poor memory and executive function in older men","volume":"56","author":"Han","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.encep.2021.09.004_bib0630","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"THe anticholinergic risk scale and anticholinergic adverse effects in older persons","volume":"168","author":"Rudolph","year":"2008","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.encep.2021.09.004_bib0635","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"issue":"2","key":"10.1016\/j.encep.2021.09.004_bib0640","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","article-title":"Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study","volume":"81","author":"Ehrt","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2021.09.004_bib0645","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000325171","article-title":"Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study","volume":"31","author":"Sittironnarit","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"6","key":"10.1016\/j.encep.2021.09.004_bib0650","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/gps.4507","article-title":"Anticholinergic effect on cognition (AEC) of drugs commonly used in older people","volume":"32","author":"Bishara","year":"2017","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.encep.2021.09.004_bib0655","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bcpt.12699","article-title":"A novel scale linking potency and dosage to estimate anticholinergic exposure in older adults: the muscarinic acetylcholinergic receptor antagonist exposure scale","volume":"120","author":"Klamer","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.encep.2021.09.004_bib0660","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12877-018-0929-6","article-title":"An anticholinergic burden score for German prescribers: score development","volume":"18","author":"Kiesel","year":"2018","journal-title":"BMC Geriatr"},{"issue":"2","key":"10.1016\/j.encep.2021.09.004_bib0665","doi-asserted-by":"crossref","first-page":"eAO4435","DOI":"10.31744\/einstein_journal\/2019AO4435","article-title":"Development of a Brazilian anticholinergic activity drug scale","volume":"17","author":"Nery","year":"2019","journal-title":"Einstein (Sao Paulo)"},{"issue":"7","key":"10.1016\/j.encep.2021.09.004_bib0670","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/ggi.13680","article-title":"Development of an anticholinergic burden scale specific for Korean older adults","volume":"19","author":"Jun","year":"2019","journal-title":"Geriatr Gerontol Int"},{"issue":"7","key":"10.1016\/j.encep.2021.09.004_bib0675","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107\u00a0medications commonly used by older adults","volume":"56","author":"Chew","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.encep.2021.09.004_bib0680","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1532-5415.2012.03923.x","article-title":"American Geriatrics Society updated beers criteria for potentially inappropriate medication use in older adults","volume":"60","author":"American Geriatrics Society 2012\u00a0Beers Criteria Update Expert Panel","year":"2012","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.encep.2021.09.004_bib0685","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.clpt.6100435","article-title":"Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease","volume":"84","author":"Cancelli","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.encep.2021.09.004_bib0690","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archinte.167.8.781","article-title":"A drug burden index to define the functional burden of medications in older people","volume":"167","author":"Hilmer","year":"2007","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.encep.2021.09.004_bib0695","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00228-016-2162-6","article-title":"Quantification of anticholinergic and sedative drug load with the Drug Burden Index: a review of outcomes and methodological quality of studies","volume":"73","author":"Wouters","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.encep.2021.09.004_bib0700","first-page":"003","article-title":"Rating the delirogenic potential of drugs for prediction of side effects in elderly psychiatric inpatients","volume":"1","author":"Hefner","year":"2015","journal-title":"J Pharma Pharmacovigilance"},{"issue":"6","key":"10.1016\/j.encep.2021.09.004_bib0705","first-page":"232","article-title":"Drug Delirium Scale (DDS): a tool to evaluate drugs as a risk factor for Delirium","volume":"1","author":"Nguyen","year":"2016","journal-title":"Int J Innov Res Med Sci"},{"issue":"1","key":"10.1016\/j.encep.2021.09.004_bib0710","doi-asserted-by":"crossref","first-page":"65e4","DOI":"10.1016\/j.jamda.2020.04.019","article-title":"Anticholinergic drug burden and delirium: a systematic review","volume":"22","author":"Egberts","year":"2021","journal-title":"J Am Med Dir Assoc"},{"issue":"8","key":"10.1016\/j.encep.2021.09.004_bib0715","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jagp.2013.01.012","article-title":"Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures","volume":"21","author":"Mangoni","year":"2013","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"10.1016\/j.encep.2021.09.004_bib0720","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jagp.2015.07.004","article-title":"Anticholinergic exposure during rehabilitation: cognitive and physical function outcomes in patients with delirium superimposed on dementia","volume":"23","author":"Kolanowski","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.encep.2021.09.004_bib0725","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/jgs.13932","article-title":"Anticholinergic medication use and risk of pneumonia in elderly adults: a nested case-control study","volume":"64","author":"Chatterjee","year":"2016","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.encep.2021.09.004_bib0730","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/phar.2106","article-title":"Anticholinergics influence transition from normal cognition to mild cognitive impairment in older adults in primary care","volume":"38","author":"Campbell","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.encep.2021.09.004_bib0735","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0891988718757370","article-title":"Drugs with anticholinergic potential and risk of falls with hip fracture in the elderly patients: a case-control study","volume":"31","author":"Machado-Duque","year":"2018","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"13","key":"10.1016\/j.encep.2021.09.004_bib0740","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1017\/S0033291717003774","article-title":"Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?","volume":"48","author":"Ballesteros","year":"2018","journal-title":"Psychol Med"},{"issue":"9","key":"10.1016\/j.encep.2021.09.004_bib0745","doi-asserted-by":"crossref","first-page":"e1284","DOI":"10.4088\/JCP.17m11523","article-title":"Anticholinergic burden and cognition in older patients with schizophrenia","volume":"78","author":"Tsoutsoulas","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2021.09.004_bib0750","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ajp.2019.10.013","article-title":"The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia","volume":"46","author":"Kim","year":"2019","journal-title":"Asian J Psychiatr"},{"issue":"6","key":"10.1016\/j.encep.2021.09.004_bib0755","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/JCP.0000000000000790","article-title":"The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia","volume":"37","author":"Ang","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.encep.2021.09.004_bib0760","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/jnnp-2018-318190","article-title":"Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort","volume":"89","author":"Ziad","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.encep.2021.09.004_bib0765","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2017.03.034","article-title":"Cognitive burden of anticholinergic medications in psychotic disorders","volume":"190","author":"Eum","year":"2017","journal-title":"Schizophr Res"},{"issue":"6","key":"10.1016\/j.encep.2021.09.004_bib0770","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jagp.2015.12.011","article-title":"Anticholinergic medication use and risk of dementia among elderly nursing home residents with depression","volume":"24","author":"Chatterjee","year":"2016","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"10.1016\/j.encep.2021.09.004_bib0775","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1111\/jgs.13647","article-title":"Health, aging and body composition study. Concordance between anticholinergic burden scales","volume":"63","author":"Naples","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.encep.2021.09.004_bib0780","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1365-2125.2012.04411.x","article-title":"Higher anticholinergic drug scale (ADS) scores are associated with peripheral but not cognitive markers of cholinergic blockade. Cross sectional data from 21\u00a0Norwegian nursing homes","volume":"75","author":"Kersten","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.encep.2021.09.004_bib0785","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.euroneuro.2016.08.004","article-title":"Systematic prevention of severe constipation induced by antipsychotic agents: a quasi-experimental study","volume":"26","author":"Bulot","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"10.1016\/j.encep.2021.09.004_bib0790","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2174\/138920011796504518","article-title":"Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients","volume":"12","author":"de Leon","year":"2011","journal-title":"Curr Drug Metab"},{"issue":"6","key":"10.1016\/j.encep.2021.09.004_bib0795","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bcpt.12744","article-title":"Anticholinergic exposure in a cohort of adults aged 80\u00a0years and over: associations of the MARANTE scale with mortality and hospitalization","volume":"120","author":"Wauters","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.encep.2021.09.004_bib0400","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12877-020-01671-z","article-title":"Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale","volume":"20","author":"Suh","year":"2020","journal-title":"BMC Geriatr"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001370062100227X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001370062100227X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T17:40:32Z","timestamp":1757958032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001370062100227X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S001370062100227X"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2021.09.004","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les \u00e9chelles anticholinergiques\u00a0: usage en psychiatrie et mise \u00e0 jour de l\u2019\u00e9chelle d\u2019impr\u00e9gnation anticholinergique","name":"articletitle","label":"Article Title"},{"value":"L'Enc\u00e9phale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.encep.2021.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 L'Enc\u00e9phale, Paris.","name":"copyright","label":"Copyright"}]}}